KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Income from Continuing Operations (2016 - 2025)

Arbutus Biopharma's Income from Continuing Operations history spans 13 years, with the latest figure at 7730000.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 60.81% year-over-year to 7730000.0; the TTM value through Sep 2025 reached 42257000.0, up 44.89%, while the annual FY2024 figure was 69920000.0, 4.02% up from the prior year.
  • Income from Continuing Operations for Q3 2025 was 7730000.0 at Arbutus Biopharma, down from 2502000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 2502000.0 in Q2 2025 and bottomed at 24530000.0 in Q1 2025.
  • The 5-year median for Income from Continuing Operations is 17862000.0 (2024), against an average of 16746368.42.
  • The largest annual shift saw Income from Continuing Operations crashed 37.62% in 2021 before it skyrocketed 112.64% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 21321000.0 in 2021, then dropped by 2.87% to 21932000.0 in 2022, then rose by 11.95% to 19312000.0 in 2023, then soared by 35.28% to 12499000.0 in 2024, then surged by 38.16% to 7730000.0 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Income from Continuing Operations are 7730000.0 (Q3 2025), 2502000.0 (Q2 2025), and 24530000.0 (Q1 2025).